PMID- 22272826
OWN - NLM
STAT- MEDLINE
DCOM- 20120709
LR  - 20190728
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 18
IP  - 8
DP  - 2012
TI  - Recent advances on radionuclide labeled hypoxia-imaging agents.
PG  - 1084-97
AB  - Hypoxic tissue exists in most of the solid tumors and hypoxia is a common 
      character of these tumors. The existence of hypoxic tissue in the tumor decreases 
      the efficacy of radiotherapy and chemotherapy. Radiolabeled hypoxia markers have 
      been developed to measure the hypoxic tissue together with non-invasive imaging 
      techniques such as PET, SPECT, and PET/CT. This offers a convenient approach to 
      delineate the tumor providing useful information for diagnosing cancer and 
      guiding the treatment plan. Bioreducible or-ganic compounds have been developed 
      as the hypoxia markers to probe tissue hypoxia noninvasively because they can be 
      reduced and metabolized under hypoxic conditions; form adducts with cell 
      components, and thus be trapped in the hypoxic tissue. These compounds include 
      nitroimidazoles and other redox-sensitive compounds such as BnAO and ATSM. 
      Different radionuclides have been used to label these compounds such as 
      technetium-99m, iodine-123, fluorine-18, copper-64, etc. In addition, to detect 
      hypoxia with endogenous hypoxia markers such as carbonic anhydrase IX (CA IX) and 
      hypoxia-inducible factor-1 (HIF-1), some radiolabeled tracers have also been 
      developed. This article is an overview of the progress in this area in the past 
      decade including the development of radiolabeled compounds for hypoxia detection 
      and problems associated with the hypoxia marker development.
FAU - Li, Zejun
AU  - Li Z
AD  - Beijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation 
      Chemistry Key Laboratory of Fundamental Science, College of Chemistry and 
      Molecular Engineering, Peking University, Beijing, China.
FAU - Chu, Taiwei
AU  - Chu T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Biomarkers)
RN  - 0 (Radiopharmaceuticals)
SB  - IM
MH  - Animals
MH  - Biomarkers/metabolism
MH  - Cell Hypoxia
MH  - *Drug Design
MH  - Humans
MH  - Multimodal Imaging/methods
MH  - Neoplasms/*diagnostic imaging/pathology
MH  - Positron-Emission Tomography
MH  - *Radiopharmaceuticals/chemistry
MH  - Tomography, Emission-Computed, Single-Photon/methods
MH  - Tomography, X-Ray Computed
EDAT- 2012/01/26 06:00
MHDA- 2012/07/10 06:00
CRDT- 2012/01/26 06:00
PHST- 2011/10/27 00:00 [received]
PHST- 2011/12/09 00:00 [accepted]
PHST- 2012/01/26 06:00 [entrez]
PHST- 2012/01/26 06:00 [pubmed]
PHST- 2012/07/10 06:00 [medline]
AID - CPD-EPUB-20120118-006 [pii]
AID - 10.2174/138161212799315849 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2012;18(8):1084-97. doi: 10.2174/138161212799315849.